Open Access

Erratum to: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis

  • Jessica M Nielsen1Email author,
  • Christoph Pohl2,
  • Chris H Polman1,
  • Frederik Barkhof3,
  • Mark S Freedman4,
  • Gilles Edan5,
  • David H Miller6,
  • Lars Bauer2,
  • Rupert Sandbrink2,
  • Ludwig Kappos7 and
  • Bernard MJ Uitdehaag1, 8
BMC Neurology201111:19

DOI: 10.1186/1471-2377-11-19

Received: 4 February 2011

Accepted: 4 February 2011

Published: 4 February 2011

The original article was published in BMC Neurology 2009 9:19

In our article [1], we did not declare some potential competing interests for Prof. Dr. med. Ludwig Kappos:

Declaration of competing interests:

Prof. Dr. med. Ludwig Kappos

LK has participated in the last 24 months as principal investigator, member or chair of planning and steering committees or advisory boards in corporate-sponsored clinical trials in multiple sclerosis and other neurological diseases. The sponsoring pharmaceutical companies for these trials include Actelion, Advancell, Allozyne, BaroFold, Bayer Health Care Pharmaceuticals, Bayer Schering Pharma, Bayhill, Biogen Idec, BioMarin, CLC Behring, Elan, Genmab, GeNeuro SA, Genmark, GlaxoSmithKline, Lilly, Merck Serono, MediciNova, Novartis, Novonordisk, Peptimmune, sanofi-aventis, Santhera, Roche, Teva, UCB and Wyeth.

I have also lectured at medical conferences or in public on various aspects of the diagnosis and management of multiple sclerosis. In many cases these talks have been sponsored by non-restricted educational grants from one or another of the above listed companies.

Honoraria and other payments for all these activities have been exclusively used for funding of research of my department.

Research and the clinical operations (nursing and patient care services) of the MS Center in Basel have been supported by non-restricted grants from one or more of these companies and by grants from the Swiss MS Society, the Swiss National Research Foundation, the European Union, the Gianni Rubatto, Novartis and Roche Research Foundations.

Notes

Authors’ Affiliations

(1)
MS Center, Department of Neurology, VU Medical Center
(2)
Bayer Schering AG
(3)
Department of Radiology, VU medical Center
(4)
Department of Neurology, The Ottawa Hospital
(5)
Department of Neurology, Hopital Pontchaillou
(6)
Department of Radiology, Queen square hospital
(7)
Department of Neurology
(8)
Department of Epidemiology and Biostatistics, VU Medical Center

References

  1. Nielsen Jessica, Pohl Christoph, Polman Chris, Barkhof Frederik, Freedman Mark, Edan Gilles, Miller David, Bauer Lars, Sandbrink Rupert, Kappos Ludwig, Uitdehaag Bernard: Prognostic implications of a carefully performed neurological assessment in patients with a first event suggestive of multiple sclerosis. BMC Neurology. 2009, 9: 19-10.1186/1471-2377-9-19.View ArticlePubMedPubMed CentralGoogle Scholar
  2. Pre-publication history

    1. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/19/prepub

Copyright

© Nielsen et al; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement